Gentian AS, a Norwegian company, with its US office at BioHealth Innovation in Rockville, Maryland is seeking collaborators to investigate if two of the biomarkers in their portfolio, cystatin C (FDA510(k) cleared) and plasma calprotectin (US research only), could potentially be useful for detection of the severely affected COVID-19 patients.
High mortality and long hospitalization are consequences of the severe cases with COVID-19 pneumonia. Gentian therefore believes that it is important to identify biomarkers that can aid in early, rapid and effective identification of the severely affected patients.
With a presence in both Norway and Maryland, Gentian welcomes the opportunity to collaborate with research/hospital institutions who want to run a trial to assess whether performing cystatin C and plasma calprotectin tests in parallel on the COVID-19 patients could provide additional information for the treating health care professionals. Gentian AS encourages interested researchers/institutions to reach out on www.gentian.com or through email: This email address is being protected from spambots. You need JavaScript enabled to view it..
For more information: https://www.gentian.com/news/covid19-corona-calprotectin-cystatinc-biomarker